Mutations at
codon 641 of EZH2 are recurrent in germinal center
B cell lymphomas, and the most common variants lead to altered EZH2 enzymatic activity and enhanced tri-methylation of
histone H3 at
lysine 27, a repressive
chromatin modification. As an initial step toward screening patients for
cancer genotype-directed
therapy, we developed a screening assay for EZH2
codon 641 mutations amenable for testing
formalin-fixed clinical specimens, based on the sensitive SNaPshot single
nucleotide extension technology. We detected EZH2 mutations in 12/55 (22%)
follicular lymphomas (FL), 5/35 (14%) diffuse large
B cell lymphomas with a germinal center immunophenotype (GCB-DLBCL), and 2/11 (18%) high grade
B cell lymphomas with concurrent rearrangements of BCL2 and MYC. No EZH2 mutations were detected in cases of
Burkitt lymphoma (0/23). EZH2 mutations were frequently associated with the presence of BCL2 rearrangement (BCL2-R) in both the FL (28% of BCL-R cases versus 0% of BCL2-WT cases, p<0.05) and GCB-DLBCL groups (33% of BCL2-R cases versus 4% of BCL2-WT cases, p<0.04), and across all
lymphoma types excluding BL (27% of BCL2-R cases versus 3% of BCL2-WT cases, p<0.003). We confirmed gain-of-function activity for all previously reported EZH2
codon 641 mutation variants. Our findings suggest that EZH2 mutations constitute an additional genetic "hit" in many BCL2-rearranged germinal center
B cell lymphomas. Our work may be helpful in the selection of
lymphoma patients for future trials of pharmacologic agents targeting EZH2 and EZH2-regulated pathways.